

Risk-Assessment Drug Product Quality Attributes

**DIA Annual Meeting
San Antonio, TX
June 27, 2003**

Vilayat A. Sayeed, Ph.D.
OSD, FDA

Drug Product Attributes

Drug substance assigned low risk status

General Principle Followed for Developing Drug Product Attributes

**DS/DP characterization
Mechanism of product performance
Manufacturing technology*

Drug Product Attributes

**Dosage form Characteristics
Marketing History
Release and Stability Assessment**

Drug Product Attributes

Dosage form Characteristics

**Dosage Form
Strength
Physical Attributes**

Drug Product Attributes

Dosage forms

**IR oral solids
oral solutions
non sterile topical solutions
and
sterile solution of simple salts**

Drug Product Attributes

Strength

**IR Solids: Strength per unit NLT 1 mg or 1% w/w
Oral/topical solutions drug substance
concentration in drug vehicle is LT 50%
and
sterile solutions of simple salts
drug substance concentration in drug vehicle is LT
75%**

Drug Product Attributes

Physical Attributes

**Are differences in physical attributes of
ingredients used in manufacture of drug
product reported to impact product
performance?**

Drug Product Attributes

Marketing History

**Has the DP been on market for five years, with
two years real time stability data available
on a minimum of three commercial
batches?**

Drug Product Attributes

Release and Stability Assessment

**Release & Stability Specifications
Product Degradation Profile
Product Storage**

Drug Product Attributes

Release and Stability Specification

**Does the drug product specification conform
to contemporary standards?**

Drug Product Attributes

Product Degradation Profile

**Is the drug product degradation profile
predictable and are degradants
controlled?**

No known toxic impurities or degradants

Drug Product Attributes

Product Storage

Is the drug product stored at CRT and required no special packaging?

Drug Product Attributes

Drug product to qualify as candidate for low risk assignment

Dosage form Characteristics
Marketing History
Release and Stability Assessment

Acknowledgement

- **Drug Product Working Group**
- **Devinder Gill**
- **San Borlag**
- **Liang Zhou**
- **Sheldon Markofsky**